Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M304,591Revenue (TTM) $M71,595Net Margin (%)22.0Altman Z-Score5.1
Enterprise Value $M291,147EPS (TTM) $5.7Operating Margin %27.5Piotroski F-Score8
P/E(ttm)19.8Beneish M-Score-2.5Pre-tax Margin (%)26.9Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %4.2Quick Ratio2.4Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %5.9Current Ratio2.7Lower Leverage y-yN
Price/Free Cash Flow23.3y-y EBITDA Growth Rate %6.9ROA % (ttm)11.6Higher Current Ratio y-yY
Dividend Yield %2.8PEG3.4ROE % (ttm)21.9Less Shares Outstanding y-yY
Payout Ratio %54.0Shares Outstanding M2,721ROIC % (ttm)28.9Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJTweedy Browne 2016-09-30 Reduce-0.81%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -7.39%2,978,783
JNJYacktman Fund 2016-09-30 Reduce-0.69%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -11.11%3,200,000
JNJDonald Yacktman 2016-09-30 Reduce-0.53%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -7.91%6,143,753
JNJYacktman Focused Fund 2016-09-30 Reduce-0.46%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -7.69%1,800,000
JNJJoel Greenblatt 2016-09-30 Add0.32%$117.27 - $125.4
($121.32)
$ 111.96-8%Add 4262.88%214,043
JNJFirst Eagle Investment 2016-09-30 Reduce-0.22%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -96.29%28,177
JNJRobert Olstein 2016-09-30 Reduce-0.18%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -26.83%30,000
JNJBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce-0.16%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -6.63%12,334,416
JNJJohn Paulson 2016-09-30 Reduce-0.12%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -72.66%35,000
JNJRichard Pzena 2016-09-30 Reduce-0.08%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -9.13%1,002,314
JNJMichael Price 2016-09-30 Reduce-0.08%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -20.00%20,000
JNJT Rowe Price Equity Income Fund 2016-09-30 Reduce-0.01%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -0.59%3,380,000
JNJMario Gabelli 2016-09-30 Reduce-0.01%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -5.98%294,127
JNJRuane Cunniff 2016-09-30 Reduce-0.01%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -55.83%5,713
JNJCharles Brandes 2016-09-30 Reduce-0.01%$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -4.88%126,627
JNJJohn Rogers 2016-09-30 Add$117.27 - $125.4
($121.32)
$ 111.96-8%Add 0.11%858,549
JNJDodge & Cox 2016-09-30 Reduce$117.27 - $125.4
($121.32)
$ 111.96-8%Reduce -0.57%34,985
JNJYacktman Focused Fund 2016-06-30 Reduce-0.87%$108.2 - $121.3
($113.54)
$ 111.96-1%Reduce -15.22%1,950,000
JNJTweedy Browne 2016-06-30 Reduce-0.5%$108.2 - $121.3
($113.54)
$ 111.96-1%Reduce -4.93%3,216,513
JNJBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Reduce-0.35%$108.2 - $121.3
($113.54)
$ 111.96-1%Reduce -13.81%13,210,591
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PRINCE CHARLESDirector 2016-10-21Buy875$114.11-1.88view
Caruso Dominic JExec VP, Finance; CFO 2016-07-26Sell41,146$125.01-10.44view
Kapusta Ronald AController, CAO 2016-07-22Sell2,935$125.01-10.44view
Pruden Gary JExec VP, WW Chair, Med Devices 2016-06-07Sell9,735$116.03-3.51view
Kapusta Ronald AController, CAO 2016-06-07Sell3,000$115.79-3.31view
Kapusta Ronald AController, CAO 2016-05-10Sell3,957$114.77-2.45view
Stoffels PaulusChief Scientific Officer 2016-02-17Sell125,000$102.439.3view
Fasolo PeterVP, Global Human Resources 2016-02-03Sell151,385$104.127.53view
Ullmann Michael HVP, General Counsel 2015-11-20Sell17,650$102.479.26view
Caruso Dominic JVP, Finance; CFO 2015-11-02Sell20,569$102.219.54view

Press Releases about JNJ :

Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
    US Market Indexes Lower to Start the Week Nov 28 2016 
    Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy Nov 28 2016 
    Small-Cap Biotech Is on Front Lines of Fight Against Depression Nov 22 2016 
    Richard Perry Exits AIG, Time Warner Nov 14 2016 
    RA Drug Comparison Yields Mixed Results Nov 14 2016 
    Johnson & Johnson Expect it to Deliver Consistent Results Nov 08 2016 
    Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
    Dividend Aristocrats in Focus Part 24: Johnson & Johnson Nov 01 2016 
    AbbVie Reports 3rd Quarter Results Nov 01 2016 

    More From Other Websites
    Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment Dec 04 2016
    Novartis CEO plays down prospects for Actelion bid - Blick Dec 04 2016
    J&J Plans to Appeal Staggering $1B Judgment Against Hip Implant Dec 02 2016
    J&J’s Raised Offer for Actelion Said North of $250 a Share Dec 02 2016
    Actelion's silence has hedge funds betting big on J&J deal Dec 02 2016
    Actelion's silence has hedge funds betting big on J&J deal Dec 02 2016
    Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche Dec 02 2016
    Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
    5 Things You Must Know Before the Market Opens Friday Dec 02 2016
    Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
    Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
    Dallas Jury Returns $1 Billion-Plus Verdict in Defective DePuy Hip Implants Lawsuit Dec 01 2016
    Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
    Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
    Johnson & Johnson hit with over $1 billion verdict on hip implants Dec 01 2016
    Johnson & Johnson hit with over $1 bln verdict on hip implants Dec 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)